OncoCyte Corporation (OCX)

NASDAQ: OCX · Real-Time Price · USD
2.900
-0.090 (-3.01%)
Nov 4, 2024, 4:00 PM EST - Market closed
-3.01%
Market Cap 48.82M
Revenue (ttm) 1.02M
Net Income (ttm) -36.80M
Shares Out 16.84M
EPS (ttm) -3.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 21,566
Open 2.960
Previous Close 2.990
Day's Range 2.885 - 2.960
52-Week Range 2.080 - 4.340
Beta 1.00
Analysts Buy
Price Target 4.06 (+40.0%)
Earnings Date Nov 11, 2024

About OCX

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design an... [Read more]

Sector Healthcare
Founded 2009
Employees 46
Stock Exchange NASDAQ
Ticker Symbol OCX
Full Company Profile

Financial Performance

In 2023, OncoCyte's revenue was $1.50 million, an increase of 56.89% compared to the previous year's $958,000. Losses were -$28.72 million, -60.88% less than in 2022.

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for OCX stock is "Buy." The 12-month stock price forecast is $4.06, which is an increase of 40.00% from the latest price.

Price Target
$4.06
(40.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Ev...

19 days ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

3 months ago - Seeking Alpha

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics compa...

4 months ago - GlobeNewsWire

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation  (Nasdaq: OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney ...

5 months ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Jeff Ramson - Investor Relations Josh Riggs - President and Chief Executive Officer Con...

6 months ago - Seeking Alpha

Oncocyte Reports First Quarter 2024 Financial Results

IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation  (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024.

6 months ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q4 2023 Results Conference Call April 12, 2024 8:00 AM ET Company Participants Jeff Ramson - PCG Advisory Josh Riggs - President, CEO Conference Call Participants Mi...

7 months ago - Seeking Alpha

Oncocyte Reports Full Year 2023 Financial Results

IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation  (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023.

7 months ago - GlobeNewsWire

Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results

IRVINE, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that the company will release its fourth quarter and full year 2...

7 months ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q3 2023 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Stephanie Prince - IR, PCG Advisory Josh Riggs - President & CEO Conference Call Pa...

1 year ago - Seeking Alpha

OncoCyte Corporation (OCX) Q2 2023 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q2 2023 Earnings Conference Call August 10, 2023 8:00 AM ET Company Participants Stephanie Prince - PCG Advisory, IR Josh Riggs - President and CEO Conference Call P...

1 year ago - Seeking Alpha

VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients

- Blood-based test differentiates between ABMR and IgAN, enabling faster and more effective treatment- Improved utility over standard of care tests- Paper published in peer-reviewed journal

1 year ago - GlobeNewsWire

Oncocyte Announces 1-For-20 Reverse Stock Split

IRVINE, Calif., July 24, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX) (the “Company”), a precision diagnostics company, announced today that the Company will implement a 1-for-20 revers...

1 year ago - GlobeNewsWire

Oncocyte Begins Manufacturing Transplant Blood Test

Over 1 million annual testing opportunities in US Q4 targeted for early access launch IRVINE, Calif., June 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics comp...

1 year ago - GlobeNewsWire

Oncocyte Corporation to Present at the LD Micro Invitational XIII

Irvine, California--(Newsfile Corp. - June 1, 2023) - Oncocyte Corporation (NASDAQ: OCX) announced today that it will be presenting at the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevar...

1 year ago - Newsfile Corp

Oncocyte Reports First Quarter 2023 Financial Results

IRVINE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation  (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the first quarter 2023, ended March 31, 2023...

1 year ago - GlobeNewsWire

Oncocyte To Announce First Quarter 2023 Financial Results

IRVINE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its first quarter 2023 financial results on...

1 year ago - GlobeNewsWire

Oncocyte Presents New Data at AACR

IRVINE, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation  (Nasdaq: OCX), a precision diagnostics company, today announced that five posters of original research are being presented at t...

1 year ago - GlobeNewsWire

Oncocyte Announces Reduction in Force

IRVINE, Calif., April 12, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced a reduction in force involving approximately 20% of its workforc...

1 year ago - GlobeNewsWire

Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer

IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed publication of the results of a study applying ...

1 year ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q4 2022 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q4 2022 Earnings Conference Call April 3, 2023 8:30 AM ET Company Participants Caroline Corner - Investor Relations Joshua Riggs - President and Chief Executive Offi...

1 year ago - Seeking Alpha

Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K

IRVINE, Calif., March 31, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced plans to file a Form 12b-25 with the U.S. Securities and Exchang...

1 year ago - GlobeNewsWire

Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call

IRVINE, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it has changed the date of its previously announced earning...

1 year ago - GlobeNewsWire

Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results

IRVINE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, announced today that it will release its fourth quarter and full year 2022 finan...

1 year ago - GlobeNewsWire

Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer

IRVINE, Calif., March 02, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced that Joshua Riggs has been appointed as its Chief Executive Offi...

1 year ago - GlobeNewsWire